Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom

被引:29
作者
Baril, Laurence [1 ]
Rosillon, Dominique [1 ]
Willame, Corinne [1 ]
Angelo, Maria Genalin [1 ]
Zima, Julia [1 ]
van den Bosch, Judith H. [2 ]
Van Staa, Tjeerd [3 ]
Boggon, Rachael [3 ]
Bunge, Eveline M. [2 ]
Hernandez-Diaz, Sonia [4 ]
Chambers, Christina D. [5 ]
机构
[1] GSK Vaccines, B-1300 Wavre, Belgium
[2] Pallas, Hlth Res & Consultancy, Rotterdam, Netherlands
[3] CPRD Res Grp, London, England
[4] Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA
[5] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
关键词
Spontaneous abortion; Human papillomavirus vaccine; Pregnancy; Safety; Vaccine; Mathematical model; PRACTICE RESEARCH DATABASE; POOLED ANALYSIS; SAFETY; SURVEILLANCE; MEDICATIONS; UTILITY; STATES; GPRD;
D O I
10.1016/j.vaccine.2015.07.024
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: We assessed the risk of spontaneous abortion (SA) after inadvertent exposure to HPV-16/18-vaccine during pregnancy using an observational cohort design. Methods: The study population included women aged 15-25 years registered with the Clinical Practice Research Datalink General Practice OnLine Database in the United Kingdom (UK), who received at least one HPV-16/18-vaccine dose between 1st September 2008 and 30th June 2011. Exposed women had the first day of gestation between 30 days before and 45 days (90 days for the extended exposure period) after any HPV-16/18-vaccine dose. Non-exposed women had the first day of gestation 120 days-18 months after the last dose. SA defined as foetal loss between weeks 1 and 23 of gestation (UK definition). Results: The frequency of SA was 11.6% (among 207 exposed) and 9.0% (632 non-exposed), women: hazard ratio (HR) adjusted for age at first day of gestation 1.30 (95% confidence interval: 0.79-2.12). Sensitivity analysis per number of doses administered (-30 to +45-day risk period) showed a HR for SA of 1.11 (0.64-1.91) for 18/178 women with one dose during the risk period versus 2.55 (1.09-5.93) in 6/29 women with two doses within a 4-5 weeks period. The proportion of pre-term/full-term/postterm deliveries, small/large for gestational age infants, and birth defects was not significantly different between exposed and non-exposed women. Results were consistent using a (United States) SA definition of foetal loss between weeks 1-19 and/or the extended risk period. Conclusion: There was no evidence of an increased risk of SA and other adverse pregnancy outcomes in young women inadvertently HPV-16/18-vaccinated around gestation. Nevertheless, women who are pregnant or trying to become pregnant are advised to postpone vaccination until completion of pregnancy. (C) 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
引用
收藏
页码:6884 / 6891
页数:8
相关论文
共 19 条
[1]   Post-licensure safety surveillance for human papillomavirus-16/18AS04-adjuvanted vaccine: more than 4 years of experience [J].
Angelo, Maria-Genalin ;
Zima, Julia ;
Da Silva, Fernanda Tavares ;
Baril, Laurence ;
Arellano, Felix .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (05) :456-465
[2]   Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme [J].
Angelo, Maria-Genalin ;
David, Marie-Pierre ;
Zima, Julia ;
Baril, Laurence ;
Dubin, Gary ;
Arellano, Felix ;
Struyf, Frank .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (05) :466-479
[3]  
[Anonymous], ANN HPV VACC COV ENG
[4]  
[Anonymous], NATL VITAL STAT REP
[5]   Data resources for investigating drug exposure during pregnancy and associated outcomes - The General Practice Research Database (GPRD) as an alternative to pregnancy registries [J].
Charlton, Rachel A. ;
Cunnington, Marianne C. ;
de Vries, Corinne S. ;
Weil, John G. .
DRUG SAFETY, 2008, 31 (01) :39-51
[6]   Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as Tools for Postmarketing Teratogen Surveillance Anticonvulsants and the Risk of Major Congenital Malformations [J].
Charlton, Rachel A. ;
Weil, John G. ;
Cunnington, Marianne C. ;
Ray, Sayantani ;
de Vries, Corinne S. .
DRUG SAFETY, 2011, 34 (02) :157-171
[7]   Identifying Major Congenital Malformations in the UK General Practice Research Database (GPRD) A Study Reporting on the Sensitivity and Added Value of Photocopied Medical Records and Free Text in the GPRD [J].
Charlton, Rachel A. ;
Weil, John G. ;
Cunnington, Marianne C. ;
de Vries, Corinne S. .
DRUG SAFETY, 2010, 33 (09) :741-750
[8]   Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention A pooled analysis of 11 clinical trials [J].
Descamps, Dominique ;
Hardt, Karin ;
Spiessens, Bart ;
Izurieta, Patricia ;
Verstraeten, Thomas ;
Breuer, Thomas ;
Dubin, Gary .
HUMAN VACCINES, 2009, 5 (05) :332-340
[9]   The identification of pregnancies within the general practice research database [J].
Devine, Scott ;
West, Suzanne ;
Andrews, Elizabeth ;
Tennis, Pat ;
Hammad, Tarek A. ;
Eaton, Susan ;
Thorp, John ;
Olshan, Andrew .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (01) :45-50
[10]  
GOV.UK, 2012, ANN HPV COV ENGL 200